Centers for Medicare & Medicaid Services (CMS) has worked with members of its CROWNWeb support teams to review federal rules and regulations.
Barriers to donation may explain why living donor kidney transplantation has been declining.
Communicating effectively about appropriate options and eliciting patient input for overactive bladder (OAB) can improve outcomes.
Dialysis is not necessarily in the patient's best interest, clinicians and ethicists say.
Confirmation of creatinine-based eGFR should be performed in select circumstances using, where appropriate, either measured GFR or cystatin C.
Some researchers are not convinced that high blood levels of omega-3 fatty acids are associated with an increased PCa risk.
Geriatric patients with CKD are at high risk for morbidity and mortality from the potential side effects of treatments.
A majority of patients on HD have hypertension, and CVD is the leading cause of death in these patients.
Although several biomarkers show promise, PCA3 has garnered substantial attention following FDA approval and its role in the diagnosis of PCa will grow.
The surgical treatment of urolithiasis has undergone a marked evolution over the past 30 years.
Innovative approaches offer the potential for effective treatments to limited target areas with improved side effect profiles.
Elderly patients face greater perioperative risks and postoperative mortality, so careful selection of surgical candidates is imperative.
The type and amount of ingested protein affects clinical outcomes such as protein-energy wasting, kidney function and even survival.
Keeping abreast of the most current treatments for idiopathic OAB can lead to improved outcomes and quality of life.
The first step in prevention is adequate and quantitative counseling regarding fluid intake, which is effective and inexpensive.
While bone loss and reduction in bone mineral density are well known consequences of ADT, the main concern is increased risk of osteoporotic fractures.
Treatment of LUTS secondary to BPH has evolved from surgical therapy to medical monotherapy, and now combination therapy.
Given the frequency with which these lesions are found, urologists and nephrologists should be familiar with their evaluation.
Many but not all cohort studies examining the relationship between hyperuricemia and CKD outcomes suggest they may be intertwined.
Emerging data suggest that thyroid hormone deficiency may be associated with greater cardiovascular morbidity and mortality in this population.
In both nutritional and activated forms, vitamin D may have side effects that are as yet under-appreciated.
Obese individuals often are rejected as renal transplant candidates in large part because of their increased risk for surgical complications and adverse outcomes.
Urologists typically treat a renal cortical mass without biopsy, but this should be re-evaluated in the era of the incidental small renal cortical neoplasm.
Scientific speculation suggests that uremic toxins, viral mediators, and immune inhibition could play a role in malignant transformation.
It is hoped that selective screening, selective biopsy, and selective therapy will further decrease the morbidity associated with screening.
The routine incorporation of NMIBC clinical practice guidelines will reduce variation in care by closing the gap on inappropriate delivery, whether over- or underuse.
The complex disease requires regular follow up and assessment of the ongoing response to therapy.
With increased incidence of obesity—and higher caloric and salt intake—in the general population, resistant hypertension is more prevalent than ever.
Given the intimate anatomical and physiological relationship of the adrenals to the kidney, an understanding of adrenal disease is imperative for urologists and nephrologists alike.
The management of patients with high-risk prostate cancer represents one of the biggest challenges today, with little consensus on optimal treatment.
Clinicians need to keep abreast of the most current treatment options for NGB, which can result in improved patient outcomes and quality of life.
Despite recent advances in the treatment of hypertension, the majority of patients with chronic kidney disease (CKD) still remain above current blood pressure (BP) targets.
A case study involving a 58-year-old man with acute gout attacks and multiple comorbidities, including hypertension and hypercholesterolemia.
Approximately 30%-50% of SLE patients have clinically evident renal disease at presentation, but renal involvement occurs in up to 60% of patients overall.
Diagnostics and treatment options for NGB are continually advancing, and clinicians need to remain up-to-date to accurately assess and optimally manage patients
Pre-existing renal osteodystrophy at the time of transplantation, reduced renal function, and transplantation-specific therapies are the main contributing factors.
As you develop and grow a home HD program, not only will you have wonderful successes, but there will also be challenges and disappointments.
A case study involving a 65-year-old man with chronic kidney disease and acute attacks of pain, swelling, and erythema in the first metatarsophalangeal joint.
This is the title of a scheduled May 12 session at the National Kidney Foundation's 2012 Spring Clinical Meetings.
A case study examines the treatment of hyperuricemia and gout in a 57-year-old postmenopausal renal transplant recipient with intermittent gout attacks.
An impressive story of a dialysis survivor who watched his daughters grow and getting married, and had the joy of knowing several grandchildren.
Patients who undergo renal transplantation require complex care that involves a diligent, multidisciplinary approach.
Short-term outcomes from early institutional experiences have confirmed the safety and feasibility of RPN, even for anatomically complex tumors.
Gout is increasingly recognized in patients with chronic kidney disease, but the proper dosing regimen for traditional agents has not been well-studied in this patient group.
An overview of how CROWNWeb, CMS' Web-based end-stage renal disease (ESRD) data-collection system, has been updated with vaccination, hospitalization, and infection data to help CMS, the ESRD Networks, and dialysis facilities better analyze patient care efforts.
In determining prostate cancer treatment, physicians should discuss preferences, values, and expectations with patients, including life expectancy, adverse events, and costs
Therapeutic options for SIADH have been significantly enhanced with the introduction of specific vasopressin receptor antagonists
Solid evidence for a survival benefit from PSA screening for prostate cancer is lacking, but the practice is more widespread in the United States than in many European countries.
Four nephrologists weigh in about the substantive differences in dialysis implementation in this country and worldwide.
George Bakris, MD, spoke about various aspects of treating hypertension in patients with chronic kidney disease.
- Gleason Score Predicts BCR in High-Risk Prostate Cancer Patients
- Statin Use Fails To Prevent Progression to Lethal Prostate Cancer
- Biomarkers Help Distinguish Prostate Cancer from Prostatitis
- Do Surgeons' Complication Rates Reflect Their Competence?
- Low Magnesium Linked to Worse Survival in Hemodialysis Patients
- Blood Pressure Variability Linked to Heart Disease, Early Death
- Lower Extremity Amputation in Diabetes Linked with Greater Death Risk
- FDA Approves Praluent for Certain Cases of High Cholesterol
- Many Cancer Patients Unaware of Ways to Preserve Fertility
- Erectile Function Worsens In Most Men After Prostate Biopsy
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)